Volume: 5 Issue: 1
Year: 2017, Page: 9-13,
Introduction: Diabetes is a group of metabolic disorders characterized by achronic hyperglycaemic condition resulting from insufficient action of insulin. CYP inhibiting drugs increase the concentration of the drugs that are substrates for the specific CYP isoforms and thus enhance the pharmacological and toxicological effects of the substrate drugs. Pioglitazone is a CYP3A4 substrate and resveratrol is a strong inhibitor. Hence, there is a chance of influence on the pharmacokinetics and pharmacodynamics of Pioglitazone.
Aims & Objectives :To capture the knowledge, attitude and self-medication practices among medical and non-medical professional course students in Tagore Educational Institutions, Chennai and to assess the effect of ‘whatsapp’ smartphone application intervention on self-medication practices among the experimental group.
Materials &Methods :The study was performed on male wistar rats, divided into five groups. Diabetes was induced by administration of Streptozotocin 45mg/kg in 0.1M citrate buffer. Diabetic rats weretreated with resveratrol before administration of pioglitazone. Blood samples were collected from orbital puncture at various time intervals and analysed for blood glucose and pharmacokinetics of pioglitazone by HPLC.
Results :Mean serum concentration (mcg/ml) of pioglitazone increased in diabetic rats supplemented with resveratrol.
Conclusion :The results of increased pioglitazone levels as a result of its metabolic inhibition under resveratrol exposure suggests an interaction which may be due to decreased metabolism of pioglitazone as a result of CYP3A4 and CYP2C8 inhibition.
Keywords: Type 2 diabetes, Pioglitazone, Resveratrol, Wistar rats, Pharmacokinetics.
1. Bressler R and Johnson DG. Pharmacological regulation of blood glucose levels in NIDDM. Archives of Internal Medicine 1997; pp: 836-848.
2. Angela D. M.Kashuba and Joseph S. Bertino, Jr.Mechanisms of Drug Interactions I
3. Hardman G, Limbird LE and Goodman AG. Insulin, oral Hypoglycemic agents and the pharmacology of endocrine pancreas. In:Goodman&Gilman,s the pharmacological basis of therapeutics. McGraw-Hill, New York, 2006; pp.1492-1517.
4. Morgan D. Fullerton and Gregory R. Steinberg SIRT1 Takes a Backseat to AMPK in the Regulation of Insulin Sensitivity by resveratrol in Diabetes 2010; 59(3):551–553.
5. Nagao K, Jinnouchi T, Kai S and Yanagita T. Effect of dietary resveratrol on the metabolic profile of nutrients in obese OLETF rats. Lipids Health Disease 2013; 12(8): 222-226.
6. SilvieTimmers, Johan Auwerx and Patrick Schrauwen.The journey of resveratrol from yeast to human AGING 2012; 4(3): 331-333.
7. Buchner, Iselde, et al. "Hepatoprotective and Antioxidant Potential of Organic and Conventional Grape Juices in Rats Fed a High-Fat Diet." Antioxidants 2014; 3(2) 323-338.
8. Akbarzadeh A, Nourouseind. “Induction of diabetes in rats”. Journal of clinical biochemistry 2007; 22(2):60-64.
9. Chan WK and Delucchi AB. “Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.” Life Sciences 2000; 67(25): pp.3103–3112.
Raju Devde, Narasimha Reddy Y, Sravanthi K, Abid Ali, Imran Khan.Effects of Resveratrol on pharmacokinetics and pharmacodynamics of Pioglitazone in Diabetic rats.Perspectives in medical research 2017;5(1):9-13.